Table 3 The baseline characteristics between survivor and death groups
| Â | Survivor group (365) | Death group (50) | OR(95%CI) | P* |
|---|---|---|---|---|
Age, y (Mean SD) | 67.09 ± 9.68 | 71.49 ± 10.27 |  | 0.005 |
NIHSS score, median (IQR) | 10(7–13) | 18(14–20) |  | <0.001 |
D-dimer, median (IQR) | 1.80(1.10–2.70) | 3.85(1.98–4.65) |  | <0.001 |
INR, median (IQR) | 1.35(1.09–1.93) | 1.40(1.13–2.03) |  | 0.722 |
CHA2DS2-VASc, median (IQR) | 4.00(4–5) | 4.0(4–5) |  | 0.676 |
Infarct volume, ml, median (IQR) | 61(34.5–102.5) | 118(60.8–135.3) |  | <0.001 |
CURB-65 score, median (IQR) | 2(1–2) | 3(2–3) |  | <0.001 |
Females, n(%) | 187(51.23) | 24(48.00) | 0.88 (0.49–1.59) | 0.668 |
Male, n(%) | 178(48.77) | 26(52.00) | 0.88 (0.49–1.59) | 0.668 |
BMI ≥ 24 kg/m, n(%) | 110(30.14) | 13(26.00) | 0.81(0.42–1.59) | 0.548 |
Hypertension, n(%) | 233(63.84) | 32(64.00) | 1.01(0.54–1.86) | 0.982 |
Current Smoking, n(%) | 106(29.04) | 20(40.00) | 1.63(0.89–3.00) | 0.114 |
Current alcohol drinking, n(%) | 124 (33.97) | 23(46.00) | 1.66(0.91–3.01) | 0.095 |
Diabetes, n(%) | 112(30.68) | 11(22.00) | 0.64(0.32–1.29) | 0.207 |
Hyperlipidemia, n(%) | 147(40.27) | 31(62.00) | 0.78(0.42–1.44) | 0.424 |
Family history of stroke, n(%) | 86(23.56) | 8(16.00) | 0.62(0.28–1.37) | 0.231 |
Thrombolytic therapy, n(%) | 43(11.78) | 816.00) | 1.43(0.63–3.24) | 0.394 |
Thrombectomy, n(%) | 18(4.93) | 5(10.00) | 2.14(0.76–6.05) | 0.142 |
Thrombolytic therapy+ Thrombectomy, n(%) | 7(1.92) | 1(2.00) | 1.04(0.13–8.67) | 0.968 |
Medications use | ||||
 Antiplatelets, n(%) | 96(26.30) | 13(26.00) | 0.99(0.50–1.93) | 0.964 |
 Lipid-lowering medications, n(%) | 213(58.36) | 28(56.00) | 0.91(0.50–1.65) | 0.752 |